Recently, many mutations have been proved capable of assessing the risk and predicting the prognosis of glioma, such as isocitrate dehydrogenase (IDH) mutation and 1p19q co-deletion, which present relatively favorable survival [4]. This evidence concerns the gene IDH2 and glioma.